# Moderna chasing ‘holy grail’ of cancer prevention

> **Open Intelligence Dossier** · First detected: 2026-11-11 19:00 UTC · Category: Business

## Executive Summary
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.

## Intelligence Brief
Moderna is pursuing what the Financial Times calls the &quot;holy grail&quot; of cancer prevention with its personalized mRNA vaccine candidate mRNA-4157, also known as V940 or intismeran, developed in partnership with Merck. The therapy uses a patient&#039;s own tumor mutations to create a custom vaccine designed to train the immune system to recognize and attack cancer cells. It is being tested in combination with Merck&#039;s PD-1 inhibitor pembrolizumab (Keytruda).


According to the Financial Times, CEO Stéphane Bancel told investors the approach could work in &quot;more cancers than melanoma&quot; and that the company is also developing an off-the-shelf universal cancer vaccine. The Seoul Economic Daily reported that Moderna is moving beyond personalized vaccines to a universal shot. Pharmaceutical Technology noted Bancel sees a future for the personalized vaccine that could eclipse Keytruda, which generated $25 billion in sales in 2023.


Pembrolizumab, marketed as Keytruda by Merck, is a humanized monoclonal IgG4 antibody that blocks the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2 and releasing immune inhibition against tumor cells. OC Academy notes it was approved by the FDA in September 2014 as a breakthrough therapy for metastatic melanoma and is also used for non-small cell lung carcinoma, Hodgkin lymphoma, urothelial carcinoma, and cutaneous squamous cell carcinoma. Common side effects occur in 20% or more of patients; serious adverse reactions include renal failure, dyspnoea, pneumonia, and cellulitis. Immune-mediated adverse effects include pneumonitis, colitis, hypophysitis, thyroid disorders, nephritis, and hepatitis.


Johns Hopkins Medicine and Newswise reported that cancer vaccines show promise for both treatment and prevention, with personalized neoantigen vaccines and preventive vaccines targeting viruses like HPV and hepatitis B, as well as vaccines for high-risk genetic syndromes such as Lynch syndrome. The Royal Examiner described the personalized vaccine as &quot;made for one patient at a time&quot; showing promise against melanoma.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| OC Academy | Can Intismeran with Pembrolizumab Halt Melanoma Relapse? | [Source Link](https://news.google.com/rss/articles/CBMifkFVX3lxTFA4WF9vbkRFdlpYS1FfT0UxVzNWblVBS3BHMXVTZTJ4WW5CM0F2azZCaVlmNzNjMmN3X3pEY3ZrenZ4RXBqaE5lZzNoNVZBRUpwOWc2bkk0OFQybDVTZWlqZ0NKaWNMRzg4eDZOOG1jOXF5eS1IdDhfbWdpdUpDQQ?oc=5) |
| Newswise | Cancer Vaccines Show Promise for Treatment and Prevention | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxQQmlUaFU4dTgxSFRtUG4wUlpINlVDTFFnazZiT3ZxWTFobFBhS25QLXlXNDljWE1HSWN2Xy1ta0dPNTNRcGVhbDVwRG5GeXVyMkpLM0lodjU4d1QxODJnZFVoVWg5ZkplMGVZX3BtVDBOTC1iMkgydDM4VkJxZFYtbWUzUmpJQUQzTEZyeWktN3RTRkZFNUE?oc=5) |
| Johns Hopkins Medicine | Cancer Vaccines Show Promise for Treatment and Prevention | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxPX3JTb1VwWWFOSzMtNW83aDZDazJZWEZtT0t6RDRTWFM2R2QzdlRLRE04NUhQVkhLN2k5V2xWZ2J6Q2tsdVNkRnF0ZE13UDRRT09fLXFNemJYSlpNdU96eWthSE5fZllIRHhvb19kdFA5ZVpVUUFhZnhMYW1NR0JnZFp6ZmdiOGFhQmphOWpKcFE4TVFKRWphVTliTVdVUWpLNXFZdElpVUxNOEY5NFlacnVyODctdm4yVVUwWnI3YkRfa2s?oc=5) |
| Mirage News | Cancer Vaccines Show Promise in Treatment and Prevention | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxPa0thcFMzdlp5bzk0YW1ySXIwUkRaSU00SS05VDlBMy1iWjlmNEhSbVFrT2x0RzZXcWxxWnZvWVMxZUNHRTd4MHYtWHJ4SVJWQThrUzg3ajZYanlCSVU1U3I1cmZ1QkFBZjI0MFVpSXhUQkF3TTVwYldscGJSc1RaWTdKak5RaG85?oc=5) |
| TIKR.com | “More Cancers Than Melanoma”: Moderna Is Up 750% in 2026. Take Profits, or Buy More? | [Source Link](https://news.google.com/rss/articles/CBMi3AFBVV95cUxPVzRVWFRrZjJXSW1fa3hRdnJmcGx6Tnk2YzBqOVRGUnNBYm9JZTBVcWdMMVZ4a1libWZld19OTEpiZy0wNHVRSWc1Z1BDMElYbHFZMjhsMlItLTdPNWVZdzcxTEZodDc0eGhUWlNkZ2ZGYm83cUFjZnFpRlNRSFR6cHVLTEhNZUQwY3Q5U1NBWmhSRm95N3gxNmtFcmdHRkdyYXFVRHJVMFZEZ0FhREdZZ2pROGk5ZDRJQjBBWElsZDV4bE5YXzk1Ym9LQ25SNWplWEFCa3ZBQnZhRVBv?oc=5) |
| Oncology News Central | Personalized Cancer Vaccine Shows Promise in Melanoma Trial | [Source Link](https://news.google.com/rss/articles/CBMi2wFBVV95cUxQekdWbTdhRl96V2haU2NFZEJIUFg3YnBWX1pKVEhmV3JVWUpyRlhEM1hWQXB0cDZ5eEpaZGx4dGl5WnU0eFktTm5OM3hqeXN1Z3YwYWtOXzF1TXU0Y29KRHp3V1Q4aVo1cnJsQThlb3o1ZE16dWpZd0ZwZnZ2M0RBNlQyRHVybUdnV0hmaGxJNmNLNklESXFkdVhRdjJXVWR2b2lhclNNYWYydHoxek9uS2dULTJwTndvRFY4d1VENmtqSklTM1daR0p5U0lnVXBNV3pBYjRLSVJwRWM?oc=5) |
| TIKR.com | “More Cancers Than Melanoma”: Moderna Is Up 750% in 2026. Take Profits, or Buy More? | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxPSHMxY3JNNmFGVF9kclFwWVlFU2w1NHFCQ0hVb1Q0UWpDXzhmUVRNQnowQVVkZlFIU1J5UndSZndVY1ZGMy0wN0lKMktycHpvS183aVBlLUVYd1hLdVNIZW1YQUI4WW5LMVJ2QVVISGNvRDd5ek5LSC1XYlBFY3JfQkIwSkd1MXpMbDNrNHJJekJJWTlfd1JLLUdiVFpPcWc4aW9zbkY4RQ?oc=5) |
| Seoul Economic Daily | Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxNRXozNnh3SmNpdVdMVlZsZGpLbVAxMGc5RGdhdEFZQ2VBWGRzMk5MZVo1ZWY0OThxM0txa1hoLUJsWFp2WVNtb2hmZ0ZGOENaR0V0bkRfaE9PbnRUU3pzcUdlZWl0SkIyeWxrMVNnaTd0b1c5WnhMX0VmZlNoZDVYYUpUNm5SLVh2UDIyX3lpVHFhOEJmVThlbQ?oc=5) |
| Pharmaceutical Technology | Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine | [Source Link](https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN3l3c19TZVh2SXFjZDRTaWpPd0dLRGs3dkRBY29OWmxoN2ZDX0VHSEZaYXNqNnkzbUxLSUdRZjZSZldxNnFTQjF0NTB2RmVzMGJwMUd6d1pKUEpoYnd0dTlpcDlpcU1xd0tzemJTN3d5cGZoTV8wbS0wZVFfVDhPdmVNeVhVOGhlUDhYT1dycndOTm1vR2pxUFNfQVVhQmlmX01YNVFTOFdpVFpqNTlOVkZxbG5MdDNJYlZTalNBb0s?oc=5) |
| Royal Examiner | A Cancer Vaccine Made for One Patient at a Time Shows Promise Against Melanoma | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxPcnFUV2gxbjktdGswUFh3TEtYdVJhcHd1Wjd2UlRzSDBmRnpvSHBQVGowWUxZVWRoTEo2eHBxV0NYZ2l6REt6R3hMdGp3VlFZM0FsdEhOX3dlSFFJcWtEU0ctSXhGZVRQbHBESzRDVktGZElsM09aazc1LUZPOXN6eHZnMGtwaFVvcTdDX3NkQnZnejRacndTQnZ5Qk5wTzZ1Y1g3WHRiZ2s?oc=5) |
| TIKR.com | Moderna Stock Rises 8% in Five Sessions as CEO Sees Cancer Vaccine Working in “More Cancers Than Melanoma” | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxQdEVQckFicUdYcTFoLTRqSERWTnFtV3RmeTVHclM5b0YtS21lZmpuVTVVTDU1b1o4a29HVGxLRG0zTHN2ckowLUpMbTNGU0YyN3R5WEtoMlVwSWMyYW5rbERXbXhLMzE2clVoRl90ZHZvVlhGVzlKZFZBaHdrbmhmMy0zeDliOEk4SlVOMkpjY081LU1ubkpRZEpZWFpKS1BXMnY0bjdEa1paWjRXOWM1czRodldqd0VCUGdZZ2pHa0pQT2tJVGZnZA?oc=5) |
| Yahoo Finance | Can Moderna's First Cancer Therapy Win FDA Approval in 2027? | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNQU1sTGUydHFkVmpJb2pDR2xJMVVjY2Z5NDhJbjUyeUxZR2JVX0IwRF90YXY5cjY1NjVpX0hNVVNYc3ZtY3N0UkwtdmZoaUFzSklMbURRT3Nybm1zUGV6NWZNbHFObjNEdnBmbFYwZmtxendEb1hHQlg4dHY2cXozMTNrMzZYZnpFV3BPLXdWU0tDTzdmbE8yMFBn?oc=5) |
| Financial Times | Moderna chasing ‘holy grail’ of cancer prevention | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxPY21iQTBwT3RDZFg4dE1lRkszNHVOVTA2SEd6bWdjNjRSQVJhUWRkY19TblByWHREN1RhQWJqRTJuaUlnOGV5RzJUMHVGOHd2azQyZ1BIdVg5SVU1VUJ2RDMwNWdxZ0lMR0NuX3JNQWRzeFpYS3lQTnpzRVNPTkRzZkh2dTE?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-11/moderna-chasing-holy-grail-of-cancer-prevention*
